Tratamiento del melanoma avanzado con tafinlar (DABRAFENIB) + MEKINIST (TRAMETINIB) - page 8

EN ESTE CONTEXTO DOS FASE III

•

COMBI-D: 423 pacientes, SLP como objetivo principal, versus

dabrafenib

•

COMBI-V: 704 pacientes, SG como objetivo principal, versus

vemurafenib

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7 9,10,11,12,13,14,15,16,17,18,...29